mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.015 |
0.6 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.6 |
mRNA |
Bosutinib |
FIMM |
pan-cancer |
AAC |
0.16 |
0.6 |
mRNA |
GDC-0449 |
FIMM |
pan-cancer |
AAC |
-0.081 |
0.6 |
mRNA |
Crizotinib |
FIMM |
pan-cancer |
AAC |
-0.082 |
0.7 |
mRNA |
A-804598 |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.7 |
mRNA |
BRD-A05715709 |
CTRPv2 |
pan-cancer |
AAC |
-0.026 |
0.7 |
mRNA |
Irinotecan |
gCSI |
pan-cancer |
AAC |
-0.024 |
0.7 |
mRNA |
selumetinib:tretinoin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.016 |
0.7 |
mRNA |
PD-0325901 |
CCLE |
pan-cancer |
AAC |
-0.019 |
0.7 |